Hospital
DLP Harris Regional Hospital LLC
DLP Harris Regional Hospital LLC was paid $8.27M by Medicaid between Jan 2018 and Dec 2024, across 116 billing codes. Its largest line is 99285, emergency room visit (most serious) — 21% of everything it billed.
33Billing provider infoDLP HARRIS REGIONAL HOSPITAL LLC
SYLVA, NC 28779
SYLVA, NC 28779
33aNPI1407962046assigned 08/23/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$8.27M
24GClaims181,936
24DCodes billed116
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in North Carolina
Rank by total paid#56 of 92
Median peer was paid$11.47M
This provider vs. median0.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official LAWRENCE, CHARLOTTE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 24,444 | $689K | |
| 2019 | 27,300 | $738K | |
| 2020 | 15,858 | $493K | |
| 2021 | 27,869 | $1.07M | |
| 2022 | 29,237 | $1.59M | |
| 2023 | 29,290 | $1.82M | |
| 2024incomplete | 27,938 | $1.87M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 21% | 12,085 | 10,145 | $1.74M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 14% | 12,869 | 11,217 | $1.18M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 14% | 10,399 | 8,971 | $1.13M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.8% | 1,166 | 1,008 | $396K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 4.2% | 6,505 | 5,591 | $347K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 4.0% | 1,227 | 1,119 | $333K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | 3.6% | 340 | 314 | $301K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.5% | 7,543 | 6,244 | $292K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 3.4% | 10,113 | 8,714 | $284K |
| 41899 | Unlisted procedure, dentoalveolar structures | 3.0% | 262 | 230 | $251K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 2.5% | 8,325 | 7,101 | $211K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 1.8% | 4,478 | 3,873 | $146K |
104 more codes
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.4% | 15,530 | $117K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 1.4% | 1,044 | $115K |
| 80053 | Comprehensive metabolic panel | 1.3% | 13,703 | $109K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1.3% | 1,327 | $105K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.2% | 3,852 | $98K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 2,743 | $78K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,994 | $73K |
| 71045 | Radiologic examination, chest; single view | <1% | 3,132 | $72K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,214 | $60K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,196 | $57K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 733 | $55K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 2,721 | $55K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 3,230 | $55K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 1,801 | $49K |
| 87070 | <1% | 4,169 | $44K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 2,426 | $41K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 390 | $29K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 41 | $27K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,888 | $26K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,824 | $24K |
| 84703 | <1% | 2,514 | $23K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,866 | $23K |
| 88304 | <1% | 202 | $20K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 216 | $18K |
| 87088 | <1% | 1,917 | $18K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 823 | $18K |
| 59025 | Fetal non-stress test | <1% | 390 | $17K |
| 83690 | <1% | 2,273 | $16K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 786 | $16K |
| 84484 | <1% | 1,766 | $16K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 452 | $15K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 342 | $14K |
| 81001 | <1% | 3,354 | $11K | |
| 86780 | <1% | 666 | $10K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 141 | $10K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 1,229 | $9K |
| 87430 | <1% | 636 | $8K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 310 | $8K |
| 85610 | <1% | 2,180 | $7K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 2,553 | $7K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 259 | $6K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 242 | $6K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,109 | $5K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,090 | $4K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,074 | $4K |
| 83605 | <1% | 285 | $3K | |
| J2704 | Injection, propofol, 10 mg | <1% | 720 | $3K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 908 | $3K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 104 | $3K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 93 | $2K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 146 | $2K |
| 80306 | <1% | 116 | $2K | |
| 96376 | <1% | 71 | $2K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 615 | $2K |
| 94060 | <1% | 72 | $2K | |
| 82247 | <1% | 295 | $2K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 160 | $2K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 48 | $2K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 651 | $1K |
| 81003 | <1% | 1,065 | $1K | |
| 94729 | <1% | 50 | $1K | |
| 86850 | <1% | 111 | $1K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 27 | $1K |
| 86803 | <1% | 72 | $1K | |
| 86762 | <1% | 72 | $1K | |
| 80061 | Lipid panel | <1% | 82 | $1K |
| 87340 | <1% | 101 | $993.84 | |
| 85730 | <1% | 173 | $960.87 | |
| 87077 | <1% | 76 | $872.41 | |
| 82951 | <1% | 66 | $834.13 | |
| 87807 | <1% | 83 | $828.24 | |
| 0598T | <1% | 19 | $827.46 | |
| 87186 | <1% | 60 | $689.26 | |
| L8699 | Prosthetic implant, not otherwise specified | <1% | 55 | $666.34 |
| L8613 | Ossicula implant | <1% | 145 | $610.03 |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 51 | $597.48 |
| 84439 | <1% | 46 | $528.60 | |
| 87040 | <1% | 25 | $459.93 | |
| 86900 | <1% | 130 | $380.14 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 190 | $371.10 |
| 88142 | <1% | 18 | $353.36 | |
| 85027 | <1% | 41 | $345.97 | |
| 86901 | <1% | 108 | $321.72 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 39 | $298.40 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 31 | $260.49 |
| 94726 | <1% | 12 | $257.64 | |
| 83655 | <1% | 13 | $232.97 | |
| 87081 | <1% | 30 | $183.79 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 37 | $175.00 |
| 80076 | <1% | 12 | $159.11 | |
| 86317 | <1% | 15 | $144.64 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 102 | $137.74 |
| 83735 | <1% | 16 | $128.14 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 14 | $117.23 |
| 85660 | <1% | 15 | $104.24 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 35 | $83.19 |
| J3490 | Unclassified drugs | <1% | 27 | $82.79 |
| 82150 | <1% | 15 | $80.80 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 13 | $66.59 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 28 | $36.43 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 15 | $17.91 |
| A0425 | Ground mileage, per statute mile | 0% | 516 | $0.00 |
| A0428 | Ambulance service, basic life support, non-emergency transport, (bls) | 0% | 14 | $0.00 |
| A0427 | Emergency ambulance ride, advanced life support | 0% | 127 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLAWRENCE, CHARLOTTE (SECRETARY)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.